In conclusion, tsRNA-GlyGCC plays a tumorigenic role in CRC and promotes CRC 5-FU resistance by targeting SPIB and modulating the JAK1/STAT6 signaling pathway. Here, JAK1 is linked to colorectal carcinoma.